The combination of VS4718 and an anti-PD1 antibody can not only increase the infiltration of CD8+ T cells and reduce the infiltration of immunosuppressive Tregs and macrophages but also block the binding of PD1 on the surface of T cells to PD-L1 on the surface of tumor cells. The gene discussed is CD8A; the disease is neoplasm.